Mabxience Allies With Zentiva For European Bevacizumab Launch
Avastin Rival Alymsys Launched Shortly After Partner Stada Introduced Oyavas
Mabxience and Zentiva have partnered to launch the Alymsys bevacizumab biosimilar rival to Avastin that recently received a pan-European marketing authorization.
You may also be interested in...
Zentiva Enters A New Phase With Saltofte As CEO
Zentiva has announced that Steffen Saltofte will become CEO of the privately-owned generics firm, replacing Nick Haggar who has led the company for over four years.
Biocon And Zentiva Sign Liraglutide Deal For 30 European Countries
Zentiva gains semi-exclusive commercialization rights to Biocon’s liraglutide drug-device combination in 30 countries, following a string of similar deals for the company since its 2018 acquisition.
Celltrion Gets Ready To Face The Competition After European Bevacizumab Nod
Celltrion has received a positive opinion from the EMA’s CHMP for its Vegzelma bevacizumab biosimilar rival to Avastin, setting up the Korean firm to enter a competitive European market that already includes several bevacizumab biosimilars.